ORIGINAL_ARTICLE
Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms
Objective(s): We investigated the detectability of somatostatin receptor scintigraphy (SRS) for neuroendocrine neoplasms (NEN).
Methods: From January 2016 to October 2020, 125 SRS examinations using indium-111 pentetreotide performed for patients with NEN lesions were retrospectively evaluated. The detection rate of NEN lesions was determined according to histopathological classification by primary site and by organ.
Results: At least one NEN lesion was detected in 73% (91/125) with a positive Krenning score of ≥2 in SRS. The detection of abdominal NENs (gastrointestinal tract, 38; pancreas, 62; and others, 14) was 89% (49/55) for neuroendocrine tumor (NET)-grade (G) 1, 78% (32/41) for NET-G2, 66% (2/3) for NET-G3, 31% (4/13) for neuroendocrine carcinoma (NEC), 100% (1/1) for mixed neuroendocrine–non-neuroendocrine neoplasm, and 0% (0/1) for non-classified NEN. That of thoracic NENs was 33% (2/6) for typical carcinoid tumor and 40% (2/5) for atypical carcinoid tumor. For a total of 226 organ lesions, hepatic lesions were 76% (58/76); pancreatic lesions, 61% (31/51); lymph node lesions, 77% (27/35); bone lesions, 83% (20/24); duodenal lesions, 82% (9/11); and other lesions, 41% (11/27).
Conclusion: The detectability of SRS for NEN in Japan was verified at a center, and its usefulness was confirmed.
https://aojnmb.mums.ac.ir/article_18475_c5e177d4d75b6b024164a6b49a7d907c.pdf
2022-01-01
1
13
10.22038/aojnmb.2021.56254.1390
neuroendocrine neoplasms (NEN)
Neuroendocrine Tumor (NET)
somatostatin receptor scintigraphy (SRS)
Indium-111 pentetreotide Octreo scan
Yoshitaka
Inaba
105824@aichi-cc.jp
1
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
LEAD_AUTHOR
Susumu
Hijioka
shijioka@ncc.go.jp
2
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Isanori
Iwama
iiwama@aichi-cc.jp
3
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Tsubasa
Asai
tasai@aichi-cc.jp
4
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Hiroki
Miyamura
hmiyamur@aichi-cc.jp
5
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Shohei
Chatani
schatani@aichi-cc.jp
6
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Takaaki
Hasegawa
t-hasegawa@aichi-cc.jp
7
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Schinichi
Murata
smurata@aichi-cc.jp
8
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Mina
Kato
minajima@aichi-cc.jp
9
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Yozo
Sato
ysato@aichi-cc.jp
10
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Hidekazu
Yamaura
h_yamau@aichi-cc.jp
11
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Hiroaki
Onaya
honaya@aichi-cc.jp
12
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Junichi
Shimizu
jshimizu@aichi-cc.jp
13
Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Kazuo
Hara
khara@aichi-cc.jp
14
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
AUTHOR
Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: meta-bolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992; 33(5):652-658.
1
Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003; 24(4):389-427.
2
Kurita Y, Kuwahara T, Mizuno N, Okuno N, Matsumoto S, Toriyama K, et al. Utility of somatostatin receptor scintigraphy in pancreatic neuroendocrine neoplasms. Journal of the Japan Pancreas Society. 2019; 34(2):78-85.
3
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. WHO Classification of Tumours Editorial Board. Histopathology. 2020; 76(2):182-188.
4
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC; 2015.
5
Kubota K, Okasaki M, Minamimoto R, Miyata Y, Morooka M, Nakajima K, et al. Lesion-based analysis of (18)F-FDG uptake and (111)In-pentetreotide uptake by neuro-endocrine tumors. Ann Nucl Med 2014; 28(10):1004-1010.
6
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010; 37(7): 1441-1448.
7
Krenning EP, Valkema R, Kooij PP, Breeman WA, Bakker WH, deHerder WW, et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol. 1999; 31 Suppl 2: S219-S223.
8
Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015; 35(2):500-516.
9
Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, et ENETS Consensus Guidelines for the Standards of Care in NeuroendocrineTumors: somatostatin receptor imaging with 111In-pentetreotide. Neuroendo-crinology. 2009; 90(2):184-189.
10
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017; 3(10): 1335-1342.
11
Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol. 2008; 26(6):963-970.
12
Hasegawa S, Kobayashi N, Tokuhisa M, Goto A, Takano S, Takada Y, et al. Clinical usefulness of somatostatin receptor scintigraphy in Japanese patients with gastroenteropancreatic neuroendocrine tumors. Digestion. 2017; 96(1):13-20.
13
Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendo-crine Tumors. Neuroendocrinology. 2016; 103(2): 153-171.
14
Kulke MH, Shah MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015; 13(1):78-108.
15
Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scinti-graphy, and 18F-FDG PET. J Nucl Med. 2010; 51(5):704-712.
16
Konukiewitz B, Schlitter AM, Jesinghaus M, Pfister D, Steiger K, Segler A, et al. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol. 2017; 30(4):587-598.
17
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013; 24(1):152-160.
18
Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemo- Cancer. 2011; 117(20): 4617-4622.
19
Scigliano S, Lebtahi R, Maire F, Stievenart JL, Kianmanesh R, Sauvanet A, et al. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocr Relat Cancer. 2009; 16(3):977-990.
20
Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508-518.
21
Oh S, Prasad V, Lee DS, Baum RP. Effect of peptide receptor radionuclide therapy on somatostatin receptor status and glucose metabolism in neuroendocrine tumors: intraindividual comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. Int J Mol Imaging 2011; 2011: 524130.
22
Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, et al. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg. 1998; 22(6):588-592.
23
Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. Theranostics. 2017; 7(5): 1149-1158.
24
Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007; 34(10): 1617-1626.
25
Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide J Nucl Med. 2010; 51(6):875-882.
26
Haug AR, Rominger A, Mustafa M, Auernhammer C, Göke B, Schmidt GP, et al. Treatment with octreotide does not reduce tumor uptake of 68Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med. 2011; 52(11):1679-1683.
27
Brabander T, Teunissen J, Kwekkeboom D. Physiological uptake in the pancreatic head on somatostatin receptor scintigraphy using [111In-DTPA]octreotide: incidence and Clin Nucl Med. 2017; 42(1):15-19.
28
Sabet A, Biersack HJ, Ezziddin S. Advances in Peptide Receptor Radionuclide Therapy.Semin Nucl Med. 2016; 46(1):40-46.
29
Strosberg J, El-Haddad G, Wolin E, Hendifar A,Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017; 376(2): 125-35.
30
ORIGINAL_ARTICLE
68Ga-DOTATATE Radioisotope scan to detect neuroendocrine tumors; A Cross-Sectional Study
Objevtive(s): Neuroendocrine tumors are a heterogeneous group of neoplasms that arise from the peptide-producing cells of the neuroendocrine system. Different functional imaging methods have been suggested to diagnose NETs. There is still not enough evidence to recommend 68Ga-DOTATATE as a standard diagnostic tool in NETs. Therefore, the aim of this study was to assess the value of 68Ga-DOTATATE scan in detecting NETs.Methods: This was a cross-sectional study. All patients with a pathologically confirmed NET tumor referred to Masih Daneshvari Hospital affiliated to Shahid Beheshti University of Medical Sciences entered the study. Patients underwent a 68Ga-DOTATATE PET/CT. All statistical analysis were performed by SPSS software version 18.Results: Forty patients with a mean age of 48.1±15.80 years entered the study. Twenty-one (52.5%) were male and 19 (47.5%) female. In the studied patients, neuroendocrine tumor was present in 19 cases (47.5%) in pancreas and gastrointestinal tract, 9 (22.5%) in lung, 3 (7.5%) in mediastinum and adrenal gland, 6 cases (5%) in liver and 3 other sites. There was no significant association between mean age and gender with primary location of the tumor. The meanSUVmax was 11.62±20.02 and the the mean tumor size was 38.25±31.35 mm. The mean size of the metastasis was 40.55±24.53 mm. The mean percentage of ki-67 was 12.54±18.40. There was no significant correlation between SUVmax of the lesion and age (r=0.063, P=0.701), tumor size (r=-0.63, P=0.067) or Ki-67 (r=0.011, P=0.960). In 20 cases, metastases were reported, of which 14 were (70%) in the liver, 3 in the lungs (15%), 2 in the gastrointestinal and cervical lymph nodes, and 1 in the bones and pancreas(%5).Conclusion:68Ga-DOTA-peptide PET/CT could find the primary or metastasis sites of NETs with good quality images. In general, this modality can enhance the management in patients with NETs.
https://aojnmb.mums.ac.ir/article_19099_c71a2a2618d0b3462dfd070c234b8415.pdf
2022-01-01
14
19
10.22038/aojnmb.2021.56971.1397
68Ga-DOTA-peptide PET/CT
Neuroendocrine tumors
Diagnosis
Abtin
Doroudinia
abtin1354@gmail.com
1
Chronic Respiratory Diseases Research Center, National research institute of tuberculosis and lung diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Hadi
Emami
habib.emami@gmail.com
2
Chronic Respiratory Diseases Research Center, National research institute of tuberculosis and lung diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Mahsa
Hoseini
mdr.hosseini.m@gmail.com
3
Chronic Respiratory Diseases Research Center, National research institute of tuberculosis and lung diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, et al. Neuro-endocrine tumors. Journal of the National Comprehensive Cancer Network. 2012; 10(6):724-64.
1
Clark OH, Ajani JA, Benson AB, Berlin JD, Blaszkowsky LS, Byrd D, et al. Neuro-endocrine tumors. JNCCN Journal of the National Comprehensive Cancer Network. 2009; 7(7):712-47.
2
Cejas P, Drier Y, Dreijerink KM, Brosens LA, Deshpande V, Epstein CB, et al. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nature medicine. 2019; 25(8):1260-5.
3
The Chicago consensus on peritoneal surface malignancies: management of neuroendocrine Annals of surgical oncology. 2020:1-5.
4
Barthet M, Giovannini M, Lesavre N, Boustiere C, Napoleon B, Koch S, et al. Endoscopic ultrasound-guided radio-frequency ablation for pancreatic neuro-endocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy. 2019; 51(09):836-42.
5
Lv Y, Han X, Xu X-F, Ji Y, Zhou Y-H, Sun H-C, et al. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroentero-pancreatic neuroendocrine tumors after initial R0 surgical resection. BMC cancer. 2019; 19(1):1-9.
6
Mazzaferro V, Pulvirenti A, Coppa J. Neuro-endocrine tumors metastatic to the liver: how to select patients for liver trans-plantation? Journal of hepatology. 2007; 47(4):460-6.
7
De Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP. Tumor imaging and therapy using radiolabeled somato-statin analogues. Accounts of chemical research. 2009; 42(7):873-80.
8
Krenning E, Kwekkeboom DJ, Bakker Wea, Breeman W, Kooij P, Oei H, et al. Somatostatin receptor scintigraphy with [111 In-DTPA-D-Phe 1]-and [123 I-Tyr 3]-octreotide: the Rotterdam experience with more than 1000 patients. European journal of nuclear medicine. 1993; 20(8):716-31.
9
Simons ZB, Wangsiricharoen S, Gelwan E, Lilja SB, Santhanam P. SUN-904 Ga68 Dotatate Detects Ectopic ACTH Secreting Atypical Carcinoid Tumor. Journal of the Endocrine Society. 2020; 4(Supplement_1): SUN-904.
10
Hofman MS, Lau WE, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015; 35(2):500-16.
11
Guenter R, Aweda T, Matos DMC, Jang S, Whitt J, Cheng Y-Q, et al. Overexpression of somatostatin receptor type 2 in neuro-endocrine tumors for improved Ga68-DOTATATE imaging and treatment. Surgery. 2020; 167(1):189-96.
12
Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, Sankowski A, Modlin IM, Kidd M. Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines The Journal of Clinical Endocrinology & Metabolism. 2015; 100 (11):E1437-E45.
13
Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, de Jong M. Localisation and mechanism of renal retention of radio-labelled somatostatin analogues. European journal of nuclear medicine and molecular imaging. 2005; 32(10):1136-43.
14
Li WP, Lewis JS, Kim J, Bugaj JE, Johnson MA, Erion JL, et al. DOTA− d-Tyr1-Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and Therapy. Bioconjugate chemistry. 2002; 13(4):721-8.
15
Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncologica. 2007; 46(6):723-34.
16
Bombardieri E, Maccauro M, de Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Annals of Oncology. 2001; 12:S51-S61.
17
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017; 44(9):1588-601.
18
Gustafsson BI, Kidd M, Modlin IM. Neuro-endocrine tumors of the diffuse neuro-endocrine system. Current opinion in oncology. 2008; 20(1):1-12.
19
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastro-enteropancreatic neuroendocrine tumours. The lancet oncology. 2008; 9(1): 61-72.
20
Crown A, Rocha FG, Raghu P, Lin B, Funk G, Alseidi A, et al. Impact of initial imaging with gallium‐68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors. Journal of Surgical Oncology. 2020; 121(3):480-5.
21
Begum N, Maasberg S, Plöckinger U, Anlauf M, Rinke A, Pöpperl G, et al. Neuroendocrine tumours of the GI tract--data from the German NET Registry. Zentralblatt furChirurgie. 2012; 139(3):276-83.
22
Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol. 2012; 56(1):40-7.
23
Özkan ZG, Kuyumcu S, Balköse D, Ozkan B, Aksakal N, Yılmaz E, et al. The value of somatostatin receptor imaging with In-111 Octreotide and/or Ga-68 DOTATATE in localizing Ectopic ACTH producing tumors.Mol Imaging Radionucl Ther. 2013; 22(2): 49-55.
24
Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, et al. The impact of 68Ga-DOTATOC positron emission tomography/ computed tomography on the multimodal management of patients with neuro-endocrine tumors. Annals of surgery. 2010; 252(5):850-6.
25
Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2014; 55(4):389-98.
26
Delpassand ES, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A, et al. 64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First US Prospective, Reader-Masked Clinical Trial. Journal of Nuclear Medicine. 2020; 61(6):890-6.
27
ORIGINAL_ARTICLE
Impact of 18F-FDG PET/CT on treatment of patients with differentiated thyroid carcinoma, negative 131I whole body scan and elevated serum thyroglobulin
Objective(s): 18F-FDG PET/CT is increasingly performed in patients with differen-tiated thyroid cancer. The aim of this study was to assess the clinical impact of 18F-FDG PET/CT on the management of patients with differentiated thyroid carcinoma who had elevated serum thyroglobulin (Tg) and negative 131I whole body scan (WBS).
Methods: 67 patients with differentiated thyroid carcinoma were included in this study. The findings of 18F-FDG PET/CT imaging were compared with histo-pathology, follow up imaging, or clinical follow-up results. The diagnostic accuracy of 18F-FDG PET/CT was evaluated for the entire patient group and for those patients with stimulated serum thyroglobulin levels of less than 5, 5–10, and more than 10 pmol/L as well as for local recurrences and metastases sites. The impact of 18F-FDG PET/CT on therapeutic management was also evaluated.
Results: 30/67 patients had positive findings on 18F-FDG PET/CT; 28 were true-positive and 2 were false-positive. 18F-FDG PET/CT results were true-negative in 36 patients and false-negative in 1 patient. The overall sensitivity, specificity, accuracy, PPV and NPV of 18F-FDG PET/CT were, 96.5%, 94.5%, 95.5%, 93.3%, and 97.2% respectively. Positive 18F-FDG PET/CT findings were directly correlated with stimulated serum thyroglobulin levels, 7.1% had Tg between 5–10, and 92.9% had Tg greater than 10 pmol/L. 18F-FDG PET/CT had a high or moderate impact on treatment management in 28 (41.8%) of patients.
Conclusion: 18F-FDG PET/CT is able to improve diagnostic accuracy and have management impact in a therapeutically relevant way in patients with differentiated thyroid carcinoma who present with rising thyroglobulin level, negative 131I WBS, and clinical suspicion of recurrent disease.
https://aojnmb.mums.ac.ir/article_18856_0ec3a01563a07745f97db389ce701732.pdf
2022-01-01
20
27
10.22038/aojnmb.2021.58276.1406
FDG PET
Thyroglobulin
131I
thyroid carcinoma
Raef
Boktor
raef.boktor@austin.org.au
1
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC Australia
AUTHOR
Sze Ting
Lee
sze.ting.lee@bigpond.com
2
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC Australia
AUTHOR
Salvatore
Berlangieri
sam.berlangieri@austin.org.au
3
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC Australia
AUTHOR
Andrew
Scott
andrew.scott@onjcri.org.au
4
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC Australia
LEAD_AUTHOR
Ronga G, Fiorentino A, Paserio E, Signore A, Todino V, Tummarello M, et al. Can iodine-131 whole-body scan be replaced by Tg measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med. 1990; 31:1766–1771.
1
Roelants V, Nayer PD, Bouckaert A, Beckers C. The predictive value of serum Tg in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997; 24:722–727.
2
Filesi M, Signore A, Ventroni G, Melacrinis FF, Ronga G. Role of initial iodine- 131 whole-body scan and serum Tg in differentiated thyroid carcinoma J Nucl Med. 1998; 39:1542–1546.
3
Lamartina L, Deandreis D, Durante C, Filetti S. Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. Eur J Endocrinol. 2016; 175(5):R185-R202.
4
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26(1):1-133.
5
Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, et al. Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated Tg levels and negative 131I scanning results after therapy. J Nucl Med. 2001; 42:1464–1469.
6
Schlumberger M, Arcanglioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-rays. J Nucl Med. 1988; 29:1790 –1794.
7
Maxon H, Smith H. Radioiodine-131I in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. l990; 19:685-7l8.
8
Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated Tg and negative diagnostic scan. J Clin Endocrinol Metab. 1995; 80:1488–1492.
9
Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. FDG PET of recurrent or metastatic 131I-negative papillary thyroid J Nucl Med.2000; 41:1010–1015.
10
Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M.Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated Tg and negative 131I scan. J Nucl Med. 2001; 42:71–76.
11
Carril J, Quirce R, Serrano J, Banzo I, Jimenez-Bonilla JF, Tabuenca O, et al. Total-body scintigraphy with thallium-201 and iodine-131 in the follow up of differentiated thyroid cancer. J NucI Med. 1997; 38:686-692.
12
Unal S. Menda Y, Adalet I, Boztepe H, Ozbey N, Alagol F, et al. Thallium-201, technetium-99m-tetrofosmin and iodine-l31 in detecting differentiated thyroid carcinoma metastases. J Nucl Med. 1998; 39:1897-1902.
13
Fridrich L, Messa C, Landoni C, Lucignani G, Moncayo R, Kendler D, et al. Whole body scintigraphy with 99mTc-MIBI, 18F-FDG and 131I in patients with metastatic thyroid carcinoma. Nucl Med Commun.1997; 18:3-9.
14
Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmenter C.Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocnnol Metab. l996; 8l: 2541- 2544.
15
Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauser K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999; 26:1547–1552.
16
Shammas A, Degirmenci1 B, Mountz JM, McCook BM, Branstetter B, Badreddine B, et al. 18F-FDG PET/CT in Patients with Suspected Recurrent or Metastatic Well-Differentiated Thyroid Cancer. J Nucl Med 2007; 48:221–226.
17
Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxy-glucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med.1997; 24:1342–1348.
18
Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996; 37: 1468–1472.
19
Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med. 1987; 28:910–914.
20
Scott AM, Gunawardana DH, Kelley B, Stuckey JG, Byrne AJ, Ramshaw JE, et al. PET Changes Management and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study. J Nucl Med. 2008; 49:1451-1457.
21
Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differen-tiated thyroid carcinoma in patients with normal chest x-rays. J Nucl Med. 1988; 29: 1790–1794.
22
Meng-Jie Dong, Zhen-Feng Liu, Kui Zhao, Ling-Xiang Ruan, Guo-Lin Wang, Shu-Ye Yang, et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun, 2009; 30:639-650.
23
Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient manage ment. J Nucl Med 2006; 47: 616–624.
24
Gross ND, Weissman JL, Talbot JM, Andersen PE, Wax MK, Cohen JI. MRI detection of cervical metastasis from differentiated thyroid carcinoma. Laryngoscope. 2001; 111:1905–1909.
25
Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab. 2004; 89:3402–3407.
26
Wang W, Macapinlac H, Larson SM, Yeh SDJ, Akhurst T, Finn RD, et al. [18F]-2-fluoro-2-deoxy-D-glucosepositron emission tomo-graphy localizes residual thyroid cancer in patients with negative diagnostic 131I whole-body scans and elevated serum Tg levels. J Clin Endocrinol Metab. 1999; 84: 2291–2302.
27
Lee JW, Lee SL, Lee DH, Kim YJ. Clinical utility of F-18 FDG PET/CT concurrent with 131I therapy in intermediate – to – high risk patients with differentiated thyroid cancer: Dual centre experience with 286 patients. J Nucl Med 2013; 54: 1230-1236.
28
Qichang W, Bai L, Zhao G, Gege Z, Youjia Z, Qingjie M, et al. Diagnostic performance of 18F-FDG-PET/CT in DTC patients with Tg elevation and negative iodine scintigraphy: a meta-analysis. Eur J Endocrinol. 2019; 181: 93-102.
29
Kukulska A, Krajewska J, Kołosza Z, Paliczka-Cies Lik E, Puch Z, Gubala E, et al. The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperTgemia in a real clinical practice. Eur J Endocrinol. 2016; 175(5):379-85.
30
Kang SY, Bang J-I, Kang KW, Lee H-Y, Chung J-K. FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma. PLoS One. 2019; 14(6):e0218416.
31
Nagarajah J, Janssen M, Hetkamp P, Jentzen W. Iodine symporter targeting with 124I/131I theranostics. J Nucl Med. 2017; 58 (suppl): 34S–38S.
32
Kreissl MC, Janssen MJR, Nagarajah J. Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer. J Nuc Med. 2019; 60:9-15.
33
Jeong SY, Lee S-W, Kim HW, Song B-Il, Ahn B-C, Lee J. Clinical applications of SPECT/CT after first I-131 ablation in patients with differentiated thyroid cancer. Clin Endo crinol. 2014; 81(3):445-451.
34
ORIGINAL_ARTICLE
Observation Variation in Ultrasonography Assessment of Thyroid Nodules
Objective(s): Accurate detection and competent management of thyroid nodules, as a common disease, basically depends on the reliability of the ultrasonography (US) report. In this research, we evaluated inter and intra-observer variation among ultrasonography reporters, based on ACR-TIRADS.Methods: In this retrospective study, 345 thyroid US images of 150 patients were reviewed. Three clinicians with at least 6-year experience in thyroid US reviewed the images twice at 6-8 weeks’ intervals. Composition, echogenicity, shape, margin, and echogenic foci based on ACR-TIRADS were reported, independently. Inter and intra-observer variations were calculated based on Cohen’s Kappa statistics.Results: 345 ultrasonography images of 150 patients with thyroid nodules (83 women and 67 men) with a mean age of 65 years were reviewed. Moderate to the substantial intra-observer agreement was achieved with the highest Kapa value in the category of shape (k=0.61-0.77). For TIRADS level, the moderate intra-observer agreement was observed (k=0.42-0.46). Inter-observer agreement for the US category of thyroid nodules was obtained slightly to moderate. Composition (k=0.42 and 0.51) and echogenicity (k=0.45 and 0.46) showed the highest overall agreement and margin showed the lowest overall agreement (k=0.18 and 0.19). In assessing TIRADS level of nodules, a fair agreement was obtained (k=0.23 and 0.29) .Conclusion: Moderate to substantial intra-observer agreement and slight to moderate inter-observer variation for evaluation of thyroid nodules; shows the need for a computer-aided diagnosis system based on artificial intelligence to assist our physicians in differentiating thyroid nodule characteristics based on explicit image features. An additional training course based on ACR-TIRADS for physicians can be another useful recommendation.
https://aojnmb.mums.ac.ir/article_19249_e7933de41b3ebc40dc1f167298c09cc2.pdf
2022-01-01
28
35
10.22038/aojnmb.2021.59283.1411
Inter-observer agreement
intra-observer agreement
observation variation
Ultrasonography
Thyroid nodules
Yasaman
Sharifi
sharifiy961@mums.ac.ir
1
Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Susan
Shafiei Forumad
shafiees9@mums.ac.ir
2
Nuclear Medicine Research Center, Mashhad University of Medical Sciences ,Mashhad, Iran
AUTHOR
Hamed
Tabesh
tabeshh@mums.ac.ir
3
Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Behzad
Aminzadeh
aminzadehb@mums.ac.ir
4
Department of Radiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Parvaneh
Layegh
layeghpr@mums.ac.ir
5
Department of Radiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Abolfazl
Mahmoodzadeh
abolfazl_ma@yahoo.com
6
Department of Radiology, Faculty of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran
AUTHOR
Seyed Rasoul
Zakavi
zakavir@mums.ac.ir
7
Nuclear Medicine Research Center, Mashhad University of Medical Sciences ,Mashhad, Iran
AUTHOR
Saeid
Eslami
eslamis@mums.ac.ir
8
Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
Pitoia F, Miyauchi A. American Thyroid Association guidelines for thyroid nodules and differentiated thyroid cancer and their implementation in various care settings. Thyroid. 2016; 26(2):319-21.
1
Pemayun TG. Current Diagnosis and Management of Thyroid Nodules. Acta medica Indonesiana. 2016; 48(3):247-57.
2
Wong R, Farrell SG, Grossmann M. Thyroid nodules: diagnosis and management. The Medical journal of Australia. 2018; 209(2):92-8.
3
Zakavi SR, ZARE NS, Shafiei S, Sadeghi R, Fekri N, Mazloum KZ, et al. Which complaint has the most clinical effect on quality of life of thyroid cancer survivors in long term follow up? Iranian Journal of Nuclear Medicine. 2015; 23(1):21-6.
4
Zhuang Y, Li C, Hua Z, Chen K, Lin JL. A novel TIRADS of US classification. Biomedical engineering online. 2018; 17(1):82.
5
Choi SH, Kim E-K, Kwak JY, Kim MJ, Son EJ. Interobserver and intraobserver variations in ultrasound assessment of thyroid nodules. Thyroid. 2010; 20(2):167-72.
6
Zakavi SR, Ayati N, Zare S, Ayati A, Sadri K, Fekri N, et al. Prognostic value and optimal threshold of first thyroglobulin in low/intermediate risk DTC. The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of. 2019; 65(1):64-71.
7
Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS committee. Journal of the American college of radiology. 2017; 14(5):587-95.
8
Lamartina L, Deandreis D, Durante C, Filetti S. Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. Eur J Endocrinol. 2016; 175(5):R185-R202.
9
Grant EG, Tessler FN, Hoang JK, Langer JE, Beland MD, Berland LL, et al. Thyroid ultrasound reporting lexicon: white paper of the ACR thyroid imaging, reporting and data system (TIRADS) committee. Journal of the American college of radiology. 2015; 12(12):1272-9.
10
Middleton WD, Teefey SA, Reading CC, Langer JE, Beland MD, Szabunio MM, et al. Comparison of performance characteristics of american college of radiology TI-RADS, Korean Society of thyroid radiology TIRADS, and American Thyroid Association American Journal of Roentgenology. 2018; 210(5):1148-54.
11
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977:159-74.
12
Chang Y, Paul AK, Kim N, Baek JH, Choi YJ, Ha EJ, et al. Computer‐aided diagnosis for classifying benign versus malignant thyroid nodules based on ultrasound images: a comparison with radiologist‐based assessments. Medical physics. 2016; 43(1): 554-67.
13
Choi YJ, Baek JH, Park HS, Shim WH, Kim TY, Shong YK, et al. A computer-aided diagnosis system using artificial intelligence for the diagnosis and characterization of thyroid nodules on ultrasound: initial clinical assessment. Thyroid. 2017; 27(4):546-52.
14
ORIGINAL_ARTICLE
Sentinel lymph node mapping in post chemotherapy nonseminoma testicular cancer patients undergoing retroperitoneal lymph node dissection: A series of nine cases
Objective(s): Testicular germ cell cancers are the most common solid malignancy among young men at the age ranging between 14 and 35 years. In this study, we evaluated the feasibility of sentinel lymph node mapping using intraoperative injection of radiotracer in nonseminomatous testicular cancer patients with history of orchiectomy who were candidate for retroperitoneal lymph node dissection (RPLND) in post-chemotherapy setting.
Methods: Nine consecutive cases were included in the study. Technetium-99m-labelled phytate was injected in two divided doses in the stump of the spermatic cord, through transabdominal approach. A hand-held gamma probe was used for radio-guided retroperitoneal sentinel lymph node detection intraoperatively and confirming the location of the sentinel lymph nodes.
Results: Detection rate and the false negative rate were estimated as the main indices. The detection rate was 6/9 (66%) and the false negative rate was 0/2 (0%). Location of the dissected sentinel lymph nodes were interaortocaval (2 patients), internal iliac (1 patient), external iliac (1 patient), common iliac (2 patients), and paraaortic (1 patient).
Conclusion: Sentinel lymph node mapping technique seems to be feasible and promising in post chemotherapy non-seminoma testis cancer patients who are candidate for RPLND; however, further larger studies are needed to increase and standardize the detection rate.
https://aojnmb.mums.ac.ir/article_18476_ff17caa09def0e67391b7867dd03304c.pdf
2022-01-01
36
42
10.22038/aojnmb.2021.55218.1380
Nonseminoma
Retroperitoneal lymph node dissection
chemotherapy
Sentinel lymph node
Nuclear Medicine
Cancer
Leili
Zarifmahmoudi
zarifmahmoudi@gmail.com
1
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Hamidreza
Ghorbani
ghorbanihr@mums.ac.ir
2
Kidney transplantation complications research center, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
Ramin
Sadeghi
sadeghir@mums.ac.ir
3
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Kayvan
Sadri
sadrik@mums.ac.ir
4
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Salman
Soltani
soltanis@mums.ac.ir
5
Kidney transplantation complications research center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Atena
Aghaee
aghaeeat@mums.ac.ir
6
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
De Toni L, Šabovic I, Cosci I, Ghezzi M, Foresta C, Garolla A. Testicular cancer: Genes, environment, hormones. Frontiers in endocrinology 2019; 10408.
1
Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003; 170(1): 5-11.
2
Suleyman N, Moghul M, Gowrie-Mohan S, Lane T, Vasdev N. Classification, Epidemio-logy and Therapies for Testicular Germ Cell Tumours. J Genit Syst Disor S 2016; 3(2): 2.
3
Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK et al. AJCC Cancer Staging Manual. Springer 2017.
4
Cheng L, Albers P, Berney DM, Feldman DR, Daugaard G, Gilligan T et al. Testicular cancer (Primer). Nat Rev Dis Primers 2018; 4(1): 29.
5
Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF et al. Retroperitoneal lymph node dissection for nonsemino-matous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005; 23(12): 2781-2788.
6
Stephenson A, Klein E. Surgical management of low-stage nonseminomatous germ cell testicular cancer. BJU Int 2009; 1041362-1368.
7
Weissbach L, Bussar-Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000; 37582-594.
8
Heidenreich A, Pfister D Fau - Witthuhn R, Witthuhn R Fau - Thuer D, Thuer D Fau - Albers P, Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol 2009; 55(1): 217-224.
9
Krege S, Beyer J Fau - Souchon R, Souchon R Fau - Albers P, Albers P Fau - Albrecht W, Albrecht W Fau - Algaba F, Algaba F Fau - Bamberg M et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53(3): 478-496.
10
Cary C, Masterson TA, Bihrle R, Foster RS. Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: additional procedures and perioperative complications. Urol Oncol 2015; 33(9): 389. e 315-389. e321.
11
Ray S, Pierorazio PM, Allaf ME. Primary and post-chemotherapy robotic retroperitoneal lymph node dissection for testicular cancer: a review. Transl Androl Urol 2020; 9(2): 949.
12
Javan H, Gholami H, Assadi M, Pakdel AF, Sadeghi R, Keshtgar M. The accuracy of sentinel node biopsy in breast cancer patients with the history of previous surgical biopsy of the primary lesion: systematic review and meta-analysis of the Eur J Surg Oncol 2012; 38(2): 95-109.
13
Ansari M, Rad MA, Hassanzadeh M, Gholami H, Yousefi Z, Dabbagh VR et al. Sentinel node biopsy in endometrial cancer: systematic review and meta-analysis of the literature. Eur J Gynaecol Oncol 2013; 34(5): 387-401.
14
Sadeghi R, Gholami H, Zakavi SR, Kakhki VR, Tabasi KT, Horenblas S. Accuracy of sentinel lymph node biopsy for inguinal lymph node staging of penile squamous cell carcinoma: systematic review and meta-analysis of the literature. J Urol 2012; 187(1): 25-31.
15
Farazestanian M, Yousefi Z, Zarifmahmoudi L, Mofrad MH, Kadkhodayan S, Sadeghi R. Concordance between intracervical and fundal injections for sentinel node mapping in patients with endometrial cancer?: a study using intracervical radiotracer and fundal blue dye injections. Clin Nucl Med 2019; 44(3): e123-e127.
16
Hassanzadeh M, Farahabadi EH, Yousefi Z, Kadkhodayan S, Zarifmahmoudi L, Sadeghi R. Lymphatic mapping and sentinel node biopsy in ovarian tumors: a study using intra-operative Tc-99m-Phytate and lymphoscintigraphy imaging. J Ovarian Res 2016; 9(1): 55.
17
Sadeghi R, Asadi M, Treglia G, Zakavi SR, Fattahi A, Krag DN. Axillary concordance between superficial and deep sentinel node mapping material injections in breast cancer patients: systematic review and meta-analysis of the literature. Breast Cancer Res Treat 2014; 144(2): 213-222.
18
Sadeghi R, Tabasi K, Bazaz S, Kakhki V, Massoom A, Gholami H et al. Sentinel node mapping in the prostate cancer: meta-analysis. In Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. Centre for Reviews and Dissemination (UK) 2011.
19
Sadeghi R, Alesheikh G, Zakavi SR, Fattahi A, Abdollahi A, Assadi M et al. Added value of blue dye injection in sentinel node biopsy of breast cancer patients: do all patients need blue dye? Int J Surg 2014; 12(4): 325-328.
20
Fattahi AS, Tavassoli A, Rohbakhshfar O, Sadeghi R, Abdollahi A, Forghani MN. Can methylene blue dye be used as an alternative to patent blue dye to find the sentinel lymph node in breast cancer surgery? J Res Med Sci 2014; 19(10): 918-922.
21
Zarifmahmoudi L, Ghorbani H, Sadri K, Tavakkoli M, Keshvari M, Salehi M et al. Sentinel Node Biopsy in Urothelial Carcinoma of the Bladder: Systematic Review and Meta-Analysis. Urol Int 2019; 103(4): 373-382.
22
Satoh M, Ito A, Arai Y. Laparoscopic Retroperitoneal Lymph Node Dissection: Extraperitoneal Approach. In Endo-urological Management of Urogenital Carcinoma. Springer 2006; 209-218.
23
Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH et al. Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019; 17(12): 1529-1554.
24
Zarifmahmoudi L, Sadeghi R. Re: Radio-Guided Lymph Node Mapping in Bladder Cancer Using SPECT/CT and Intraoperative gamma-Probe Methods. Clin Nucl Med 2017; 42(4): 327.
25
Sadeghi R. Sentinel node mapping diagnostic studies warrant a unique reporting criteria: comment on Xiong et al. systematic review. Eur J Surg Oncol 2014; 40(8): 1025-1026.
26
Blok JM, Kerst JM, Vegt E, Brouwer OR, Meijer RP, Bosch JR et al. Sentinel node biopsy in clinical stage I testicular cancer enables early detection of occult metastatic disease. BJU international 2019; 124(3): 424-430.
27
Kadkhodayan S, Hasanzadeh M, Treglia G, Azad A, Yousefi Z, Zarifmahmoudi L et al. Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature. Eur J Surg Oncol 2015; 41(1): 1-20.
28
Kakhki VRD, Bagheri R, Tehranian S, Shojaei P, Gholami H, Sadeghi R et al. Accuracy of sentinel node biopsy in esophageal carcinoma: a systematic review and meta-analysis of the pertinent literature. Surgery today 2014; 44(4): 607-619.
29
Sadeghi R, Forghani MN, Memar B, Mashhadi MTR, Kakhki VRD, Abdollahi A et al. How long the lymphoscintigraphy imaging should be continued for sentinel lymph node mapping? Ann Nucl Med 2009; 23(6): 507-510.
30
Abdollahi A, Jangjoo A, Kakhki VD, Zakavi SR, Memar B, Forghani MN et al. Factors affecting sentinel lymph node detection failure in breast cancer patients using intradermal injection of the tracer. Rev Esp Med Nucl 2010; 29(2): 73-77.
31
Aliakbarian M, Memar B, Jangjoo A, Zakavi SR, Kakhki VRD, Aryana K et al. Factors influencing the time of sentinel node visualization in breast cancer patients using intradermal injection of the radiotracer. Am J Surg 2011; 202(2): 199-202.
32
Jangjoo A, Forghani MN, Mehrabibahar M, Sadeghi R. Anaphylaxis reaction of a breast cancer patient to methylene blue during breast surgery with sentinel node mapping. Acta Oncologica 2010; 49(6): 877-878.
33
ORIGINAL_ARTICLE
Diffuse FDG uptake in the bilateral lungs: hypersensitivity pneumonitis supported by low-dose CT findings
Hypersensitivity pneumonitis (HP) is an interstitial lung disease resulting from an immune-mediated response in susceptible and sensitized individuals to various inhaled antigens in the environment. Imaging diagnosis is usually based on high-resolution CT findings. Here, we present a 49-year-old man with a history of diffuse large B-cell lymphoma presented with fever and occasional cough. 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) revealed diffuse FDG uptake in the bilateral lungs. Expiratory low-dose CT simultaneously performed in PET scanning revealed centrilobular nodules and air trapping in ground glass opacities (GGO). Our imaging diagnosis was acute hypersensitivity pneumonitis (HP). Based on the results of his clinical course, blood laboratory tests, and bronchoscopy, he was diagnosed with acute HP. Diffuse pulmonary FDG uptake can be seen in the patients with acute HP. In addition, expiratory low-dose CT findings of centrilobular nodules and air trapping in GGO may be helpful for accurate diagnosis of acute HP.
https://aojnmb.mums.ac.ir/article_18443_e2319de95314dae3edce3d2bf0a5eabf.pdf
2022-01-01
43
46
10.22038/aojnmb.2021.56000.1393
18F-fluorodeoxyglucose
hypersensitivity pneumonitis
low-dose computed tomography
Positron Emission Tomography
Shun
Goto
shunmarakuja@yahoo.co.jp
1
Department of Nuclear Medicine, Saitama Medical University International Medical Center, Saitama, Japan
AUTHOR
Yohji
Matsusaka
matsusaka.yohji@gmail.com
2
Department of Nuclear Medicine, Saitama Medical University International Medical Center, Saitama, Japan
LEAD_AUTHOR
Tomohiko
Yamane
yamane@mail.ne.jp
3
Department of Nuclear Medicine, Saitama Medical University International Medical Center, Saitama, Japan
AUTHOR
Yuki
Hoshino
yuki0301@saitama-med.ac.jp
4
Department of Respiratory Medicine, Saitama Medical University Hospital, Saitama, Japan
AUTHOR
Ichiei
Kuji
kuji@saitama-med.ac.jp
5
Department of Nuclear Medicine, Saitama Medical University International Medical Center, Saitama, Japan
AUTHOR
Costabel U, Miyazaki Y, Pardo A, Koschel D, Bonella F, Spagnolo P, et al. Hyper-sensitivity pneumonitis. Nat Rev Dis Primers. 2020; 6(1):65.
1
Shiiba M, Izutsu K, Ishihara M. Early detection of intravascular large B-cell lymphoma by 18FDG-PET/CT with diffuse FDG uptake in the lung without respiratory symptoms or chest CT abnormalities. Asia Ocean J Nucl Med Biol. 2014; 2(1):65-8.
2
Wu F, Wang Z, Xing X, Yu M, Shi B. The Value of 18F-FDG PET/CT in Diagnostic Procedure of Intravascular Large B-Cell Lymphoma Presenting Fever of Unknown Origin and Pulmonary Hypertension as an Initial Clin Nucl Med. 2016; 41(6): 506-7.
3
Yamane T, Daimaru O, Ito S, Nagata T, Yoshiya K, Fukaya N, et al. Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma. Ann Nucl Med. 2008; 22(8):719-22.
4
Kazama T, Faria SC, Uchida Y, Ito H, Macapinlac HA. Pulmonary drug toxicity: FDG-PET findings in patients with Ann Nucl Med. 2008; 22(2):111-4.
5
Prabhu M, Raju S, Chakraborty D, Arora S, Kumar R. Spectrum of 18F-FDG Uptake in Bilateral Lung Parenchymal Diseases on PET/CT. Clin Nucl Med. 2020;45(1):e15-e9.
6
Win Z, Todd J, Al-Nahhas A. FDG-PET imaging in Pneumocystis carinii pneumonia. Clin Nucl Med. 2005; 30(10):690-1.
7
ntriago B, Danus M, Calvo N, Escobar J, Montero M, Kohan S, et al. Influenza-like infection can result in diffuse fluordeoxy-glucose uptake in the lungs. Clin Nucl Med. 2009; 34(10):737-8.
8
Silva CI, Churg A, Muller NL. Hyper-sensitivity pneumonitis: spectrum of high-resolution CT and pathologic findings. AJR Am J Roentgenol. 2007; 188(2):334-44.
9
Patel RA, Sellami D, Gotway MB, Golden JA, Webb WR. Hypersensitivity pneumonitis: patterns on high-resolution CT. J Comput Assist Tomogr. 2000; 24(6):965-70.
10
Selman M, Pardo A, King TE, Jr. Hyper-sensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012; 186(4):314-24.
11
Nobashi T, Kubo T, Nakamoto Y, Handa T, Koyasu S, Ishimori T, et al. 18F-FDG Uptake in Less Affected Lung Field Provides Prognostic Stratification in Patients with Interstitial Lung Disease. J Nucl Med. 2016; 57(12): 1899-904.
12
Hung BT, Wang PW, Su YJ, Huang WC, Chang YH, Huang SH, et al. The efficacy of 18F-FDG PET/CT and 67Ga SPECT/CT in diagnosing fever of unknown origin. Int J Infect Dis. 2017; 62:10-7.
13
Matsusaka Y, Kawada I, Nakahara T, Iwabuchi Y, Kawaida M, Matsusaka M, et al. Abnormal Uptake and Air Trapping in Hypersensitivity Pneumonitis Detected on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Am J Respir Crit Care Med. 2019; 200(12):1542-3.
14
Rusinek H, Naidich DP, McGuinness G, Leitman BS, McCauley DI, Krinsky GA, et al. Pulmonary nodule detection: low-dose versus conventional CT. Radiology. 1998; 209(1):243-9.
15
Karabulut N, Toru M, Gelebek V, Gulsun M, Ariyurek OM. Comparison of low-dose and standard-dose helical CT in the evaluation of pulmonary nodules. Eur Radiol. 2002; 12(11):2764-9.
16
Jahangiri P, Pournazari K, Torigian DA, Werner TJ, Swisher-McClure S, Simone CB, 2nd, et al. A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung infla-mmation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy. Eur J Nucl Med Mol Imaging. 2019; 46(1):206-16.
17
Jacquelin V, Mekinian A, Brillet PY, Nunes H, Fain O, Valeyre D, et al. FDG-PET/CT in the prediction of pulmonary function improvement in nonspecific interstitial pneumonia. A Pilot Study. Eur J Radiol. 2016; 85(12):2200-5.
18
ORIGINAL_ARTICLE
Hepatic granuloma mimicking recurrent lymphoma on 18F-FDG PET/CT in a patient with primary mediastinal diffuse large B-cell lymphoma
18F-Flurodeoxyglucose (FDG) PET/CT has been considered the modality of choice in detecting, staging, restaging and following-up with lymphoma patients. However, it has an uncertain role in differentiating hepatic lymphomatous relapse from other granulomatous diseases such as in candidiasis or sarcoidosis. Therefore, it is important to correlate the imaging findings with other modalities such as ultrasound, CT scan, MRI, and histology to direct the diagnosis and treatment. We present a case of a 33-year-old woman with large B-cell lymphoma in complete remission following treatment presenting with neutropenic fever following her final cycle of chemotherapy. Ultrasound of the abdomen and enhanced CT scan of the abdomen and pelvis were negative. The FDG PET/CT scan showed multiple FDG-avid hypodense hepatic lesions that were suggestive either of lymphoproliferative involvement or nonmalignant process. However, MRI of the abdomen performed four days later was suggestive of an infectious process, rather than a lymphoproliferative disorder. A subsequent CT-guided biopsy of a hepatic lesion showed granulomatous inflammation, with no evidence of malignancy or Tuberculosis. The patient was started on Caspofungin followed by Fluconazole. After 5 weeks, the clinical condition resolved, and the subsequent FDG PET/CT showed complete resolution of the FDG-avid multiple hepatic lesions.
https://aojnmb.mums.ac.ir/article_18854_701a7f2e9c1f77266100788c5fc758cb.pdf
2022-01-01
47
52
10.22038/aojnmb.2021.56876.1396
F-18 PET CT
large B cell lymphoma
Hepatic granuloma
hepatic candidiasis
Abdul Rahman
Akkawi
ame81@mail.aub.edu
1
Department of Clinical Diagnostic Radiology, American University of Beirut Medical Center, Beirut, Lebanon
AUTHOR
Lynn
Ezzeddine
lynn.ezzeddine@gmail.com
2
Department of Diagnostic Radiology, Saint George Hospital University Medical Center, University of Balamand, Beirut, Lebanon
AUTHOR
Rita
Chahinian
rc66@aub.edu.lb
3
Department of Clinical Diagnostic Radiology, American University of Beirut Medical Center, Beirut, Lebanon
AUTHOR
Firas
Ershaid
fe34@aub.edu.lb
4
Department of Clinical Diagnostic Radiology, American University of Beirut Medical Center, Beirut, Lebanon
AUTHOR
Diala
Merheb
merheb.diala@gmail.com
5
Department of Clinical Diagnostic Radiology, American University of Beirut Medical Center, Beirut, Lebanon
AUTHOR
Majd
Mzeihem
mmm119@mail.aub.edu
6
Department of Clinical Diagnostic Radiology, American University of Beirut Medical Center, Beirut, Lebanon
AUTHOR
Jean
El Cheikh
je46@aub.edu.lb
7
Department of Internal Medicine, Division of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon
AUTHOR
Mohamad
Haidar
mh209@aub.edu.lb
8
Department of Clinical Diagnostic Radiology, American University of Beirut Medical Center, Beirut, Lebanon
LEAD_AUTHOR
Coash M, Forouhar F, Wu C. H, Wu G. Y. Granulomatous liver diseases: a review. Journal of the Formosan Medical Association. 2012; 111(1):3-13.
1
Lamps L. W. Hepatic Granulomas: A Review with Emphasis on Infectious Causes. Archives of pathology & laboratory medicine. 2015; 139(7):867–875.
2
Luk W. H, Au-Yeung A. W, Loke T. W.K. Imaging patterns of liver uptakes on PET scan: Pearls and pitfalls. Nuclear Medicine Review. 2013; 16(2):75-81.
3
Do T. D, Neurohr C, Michl M, Reiser M. F, Zech C. J. An unusual case of primary hepatic lymphoma mimicking sarcoido-sis in MRI. Acta radiologica short 2014; 3(4): 2047981613493625.
4
Jung G, Brill N, Poll L. W, Koch J. A, Wettstein M. MRI of hepatic sarcoidosis: large confluent lesions mimicking malignancy. AJR. American journal of roentgenology. 2004; 183(1):171–173.
5
Schwerz S, Mueller M, Lindemann-Docter K, Heinzel A, Mottaghy F. M, Beheshti M. Hepatic candidiasis mimi-cking lymphoma on 18F-FDG PET/CT in a patient with T cell lymphoma. European journal of nuclear medicine and molecular imaging. 2020; 47(12):2925-2926.
6
Teyton P, Baillet G, Hindié E, Filmont J. E, Sarandi F, Toubert M. E, Moretti J. L. Hepatosplenic candidiasis imaged with F-18 FDG PET/CT. Clinical nuclear medicine. 2009; 34(7): 439–440.
7
Albano D, Bosio G, Bertoli M, Petrilli G, Bertagna F. Hepatosplenic candidiasis detected by (18)F-FDG-PET/CT. Asia Oceania journal of nuclear medicine & biology. 2016; 4(2): 106–108.
8
Endo K, Oriuchi N, Higuchi T, Iida Y, Hanaoka H, Miyakubo M, Ishikita T, Koyama K. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. International journal of clinical oncology. 2006; 11(4): 286–296.
9
Johnson L. N, Iseri O, & Knodell R. G. Caseating hepatic granulomas in Hodgkin's lymphoma. Gastroenterology. 1990; 99(6): 1837–1840.
10
Rajesh S, Bansal K, Sureka B, Patidar Y, Bihari C, Arora A. The imaging conundrum of hepatic lymphoma revisited. Insights into imaging.2015; 6(6):679–692.
11
Ozer O, Eskazan A. E, Ar M. C, Beköz H, Tabak F, Ongen G, Ferhanoglu B. Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports. Journal of medical case reports. 2009; 3:7306.
12
London J, Grados A, Fermé, C, Charmillon A, Maurier F, Deau B, Crickx E, Brice P, Chapelon-Abric C, Haioun C, Burroni B, Alifano M, Le Jeunne C, Guillevin L, Costedoat-Chalumeau N, Schleinitz N, Mouthon L, Terrier B. Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature. Medicine (Baltimore). 2014; 93(21): e121.
13
Semelka RC, Kelekis NL, Sallah S, Worawattanakul S, Ascher SM. Hepato-splenic fungal disease: diagnostic accuracy and spectrum of appearances on MR imaging. AJR Am J Roentgenol. 1997; 169(5):1311-6.
14
Alves A. M. A, Torres U. S, Velloni F. G, Ribeiro B J, Tiferes D A, D’Ippolito, G. The many faces of primary and secondary hepatic lymphoma: imaging manifesta-tions and diagnostic approach. Radiologia Brasileira. 2019; 52(5): 325–330.
15
Van Prehn J, Menke-van der Houven van Oordt C. W, de Rooij M. L, Meijer E, Bomers M. K, van Dijk K. Hepatosplenic Candidiasis without Prior Documented Candidemia: An Under recognized Diagnosis? The oncologist. 2017; 22(8): 989–994.
16
Lagana S. M, Moreira R. K, Lefkowitch J. H. Hepatic granulomas: pathogenesis and differential diagnosis. Clinics in liver disease.2010; 14(4): 605–617.
17
ORIGINAL_ARTICLE
Toxic thyroid adenoma with hypercalcemia mimicking an intra-thyroidal parathyroid adenoma
Hypercalcemia is a clinical condition characterized by elevated circulating serum calcium levels either due to raised parathyroid hormone in hyperparathyroidism or due to secondary causes of hypercalcemia without elevated parathyroid hormone levels. However, hyperthyroidism may occasionally present with incidentally detected hypercalcemia. We present a case of a 53-year-old woman with a previous history of an underlying thyroid disorder, now presented with features of hypercalcemia and mildly elevated parathyroid hormone levels. Her ultrasonography of the neck was suggestive of an intra-thyroidal parathyroid adenoma and it was localized as a tracer avid lesion within the thyroid gland on dual-phase 99mTc-sestamibi planar scintigraphy with single photon emission computed tomography/ computed tomography (SPECT/CT). However, a subsequent thyroid profile followed by 99mTc- pertechnetate thyroid scintigraphy showed a hot nodule in the thyroid gland which changed the diagnosis to a toxic thyroid adenoma. She was treated with radioactive iodine ablation and thyrotoxicosis resolved and the serum calcium levels normalized on her follow-up.
https://aojnmb.mums.ac.ir/article_18932_b0d476716e889d923087acc0b9460644.pdf
2022-01-01
53
56
10.22038/aojnmb.2021.57103.1398
Thyroid adenoma hypercalcemia
parathyroid adenoma
Sestamibi
pertechnetate
Venkata Subramanian
Krishnaraju
venkat.hc@gmail.com
1
Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
AUTHOR
Ritesh
Upadhyay
rtsh.upadhyay@gmail.com
2
Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
AUTHOR
Ashwani
Sood
sood99@yahoo.com
3
Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
LEAD_AUTHOR
Anish
Bhattacharya
anishpgi@yahoo.co.in
4
Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
AUTHOR
Bhagwant
Mittal
brmittal@yahoo.com
5
Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
AUTHOR
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26(10):1343–421.
1
Liu J, Tang X, Cheng J, Yang X, Wang Y. Persistent arthralgia, vomiting and hyper calcemia as the initial manifestations of hyperthyroidism: A case report. Mol Clin Oncol. 2017; 6(2):258–60.
2
Baxter JD, Bondy PK. Hypercalcemia of thyrotoxicosis. Ann Intern Med. 1966; 65 (3): 429-42.
3
Cheung K, Wang TS, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol. 2012; 19(2):577–83.
4
Palestro CJ, Tomas MB, Tronco GG. Radionuclide Imaging of the Parathyroid Semin Nucl Med. 2005; 35(4):266–76.
5
Melloul M, Paz A, Koren R, Cytron S, Feinmesser R, Gal R. 99mTc-MIBI scintigraphy of parathyroid adenomas and its relation to tumour size and oxyphil cell abundance. Eur J Nucl Med. 2001; 28(2):209–13.
6
Sathekge MM, Mageza RB, Muthuphei MN, Modiba MCM, Clauss RC. Evaluation of thyroid nodules with technetium-99m MIBI and technetium-99m pertechnetate. Head Neck. 2001; 23(4):305–10.
7
Földes I, Lévay A, Stotz G. Comparative scanning of thyroid nodules with technetium-99m pertechnetate and technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med. 1993; 20(4):330-3.
8
ORIGINAL_ARTICLE
18F-FDG PET-CT incidental lung findings in asymptomatic COVID-19 patients: evidences from the Italian core of the first pandemic peak
Objective(s): To illustrate incidental 18F-FDG PET-CT findings and related CT alterations of suspicious pulmonary interstitial involvement in asymptomatic oncologic patients during the first COVID-19 outbreak in the core of Italian peak.
Methods: We retrospectively evaluated the 18F-FDG PET-CT follow-up examinations performed during the first Italian COVID-19 outbreak (March 3rd-April 15th, 2020) in 10 asymptomatic oncologic patients with a highly suspicious interstitial pulmonary involvement on CT. Six cases were confirmed SARS-CoV-2 by molecular tests. The following parameters were assessed: 1) lung involvement on co-registration CT as extension (laterality, number of lobes), pattern (ground-glass opacities/GGO, consolidations, mixed) and stage (early, progressive, peak, and absorption); 2) the maximum standardized uptake value (SUVmax) of lung lesions on 18F-FDG PET.
Results: The involved lobes were 5 in 5 cases (3 confirmed SARS-CoV-2), 2-4 in 4 cases and 1 in 1 case. GGO were found in all patients; 3 cases also showed a combination of GGO and peripheral consolidations (mixed). Five cases were suggestive for an early stage of interstitial pneumonia, 4 for progressive and 1 for peak. All the lung lesions showed increased FDG uptake. In early stages SUVmax ranged from 1.5 to 11, in progressive from 3.3 to 6.8, in peak from 2.4 to 7.7. SUVmax ranged 1.5-11 in patients with only GGO and 2.8-7.7 in those with mixed pattern.
Conclusions: 18F-FDG PET-CT findings in suspected COVID-19 pulmonary involvement of asymptomatic oncologic patients showed an increase in FDG uptake of GGO and consolidations, but with a wide and apparently nonspecific range of SUVmax values.
https://aojnmb.mums.ac.ir/article_19089_0c644a94b56de340155f0771817f14ab.pdf
2022-01-01
57
63
10.22038/aojnmb.2021.58035.1405
COVID-19
interstitial pneumonia
Asymptomatic
PET-CT
FDG uptake
Alice
Bonanomi
a.bonanomi10@campus.unimib.it
1
Department of Radiology, Papa Giovanni XXIII Hospital, Bergamo, Italy
LEAD_AUTHOR
Pietro Andrea
Bonaffini
pa.bonaffini@gmail.com
2
Department of Radiology, Papa Giovanni XXIII Hospital, Bergamo, Italy
AUTHOR
Marianna
Spallino
mspallino@asst-pg23.it
3
Department of Nuclear Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy
AUTHOR
Ludovico
Dulcetta
l.dulcetta@campus.unimib.it
4
Department of Radiology, Papa Giovanni XXIII Hospital, Bergamo, Italy
AUTHOR
Paolo Niccolò
Franco
p.franco@campus.unimib.it
5
Department of Radiology, Papa Giovanni XXIII Hospital, Bergamo, Italy
AUTHOR
Clarissa
Valle
clarissa.valle.rad@gmail.com
6
Department of Radiology, Papa Giovanni XXIII Hospital, Bergamo, Italy
AUTHOR
Paolo
Marra
pmarra@asst-pg23.it
7
Department of Radiology, Papa Giovanni XXIII Hospital, Bergamo, Italy
AUTHOR
Andrea
Bruno
abruno@asst-pg23.it
8
Department of Nuclear Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy
AUTHOR
Sandro
Sironi
sandro.sironi@unimib.it
9
Department of Radiology, Papa Giovanni XXIII Hospital, Bergamo, Italy
AUTHOR
Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020; 94:154-155.
1
Inui S, Fujikawa A, Jitsu M, et al. Chest CT Findings in Cases from the Cruise Ship “Diamond Princess'' with Coronavirus Disease 2019 (COVID-19). Radiol Cardiothorac Imaging. 2020; 2(2): e200110.
2
Kronbichler A, Kresse D, Yoon S, Lee KH, Effenberger M, Shin JI. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. Int J Infect Dis. 2020; 98:180-186.
3
Qin Ch, Liu F, Yen TC, Lan X. 18F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases. Eur J Nucl Med Mol Imaging. 2020; 47(5):1281-1286.
4
Annunziata S, Bolton R C D, Kamani ChH, Prior JO, Albano D, Bertagna F et al. Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review. Pharmaceuticals (Basel). 2020; 13(11):377.
5
Setti L, Kirienko M, Dalto SC, Bonacina M, Bombardieri E. FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients. Eur J Nucl Med Mol Imaging. 2020; 47(7):1649-1656.
6
Lütje S, Marinova M, Kütting D, Attenberger U, Essler M, Bundschuh RA. Nuclear medicine in SARS-CoV-2 pandemia: 18F-FDG-PET/CT to visualize COVID-19.Nuklearmedizin. 2020; 59(03):276-80.
7
Chuang HH, Emery DJ, Campbell RM, Lu Y. FDG PET/CT in diagnosing COVID-19 infection in a cancer patient with exposure history but minimal symptoms. Clin Nucl Med. 2020; 45(8):656-658.
8
Kwee TC, Kwee RM. Chest CT in COVID-19: what the radiologist needs to know. RadioGraphics. 2020; 40(7):1848-65.
9
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. European journal of nuclear medicine and molecular imaging. 2015; 42(2):328-54.
10
Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology. 2020; 295(3):715-21.
11
Vafea MT, Atalla E, Kalligeros M, Mylona E, Shehadeh F, Mylonakis E. Chest CT findings in asymptomatic cases with COVID-19: a systematic review and meta-analysis. Clinical radiology. 2020; 75(11):876. E 33-. e39.
12
Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Annals of internal medicine. 2020; 173(5):362-7.
13
Al-Sadeq DW, Nasrallah GK. The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review. International Journal of Infectious Diseases. 2020; 98:372-80.
14
Varble N, Blain M, Kassin M, Xu S, Turkbey EB, Amalou A, et al. CT and clinical assessment in asymptomatic and pre-symptomatic patients with early SARS-CoV-2 in outbreak settings. European radiology. 2021; 31(5):3165-76.
15
Albano D, Bertagna F, Alongi P, Baldari S, Baldoncini A, Bartolomei M, et al. Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study. European Journal of Nuclear Medicine and Molecular Imaging. 2021; 48: 2871–2882.
16
Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clinical immunology. 2020; 215:108427.
17
Thornton A, Fraioli F, Wan S, Garthwaite HS, Ganeshan B, Shortman RI, et al. Evolution of 18F-FDG-PET/CT findings in patients following COVID-19 pneumonia: An Initial Investigation. Journal of Nuclear Medicine. 2021; 62:8.
18
Parekh M, Donuru A, Balasubramanya R, Kapur S. Review of the chest CT differential diagnosis of ground-glass opacities in the COVID era. Radiology. 2020; 297(3):E289-E302.
19
Migliore M, Fornito M, Palazzolo M, Criscione A, Gangemi M, Borrata F, et al. Ground glass opacities management in the lung cancer screening era. Annals of translational medicine. 2018; 6(5).
20
Zhang Y, Fu F, Chen H. Management of ground-glass opacities in the lung cancer spectrum. The Annals of thoracic surgery. 2020; 110(6):1796-804.
21
Zhuo Y, Shan F, Yang S, Zhan Y, Shi Y, Zhang Z. Advances in differential diagnosis of pulmonary ground glass opacity on high resolution computed tomography and histopathology. Radiology of Infectious Diseases. 2020; 7(1):7-11.
22
ORIGINAL_ARTICLE
Bone Scan in Identification, Assessment of Initial Extent and Response to Therapy in Polymyositis
This is a 51-year-old male who presented with abdominal pain, bilateral proximal upper and lower extremities pain and weakness, and decreased urine output with abnormal kidney function test; Urea and creatinine levels were elevated at 231.5 mg/dl and 11.05 mg/dl, respectively. Initial bone scan showed increased uptake within several muscles suspicious for polymyositis, this was confirmed by biopsy of the right triceps, identified by bone scan as the best superficial biopsy site. Pelvis and thigh MRI demonstrated diffuse hyperintense signal on fluid sensitive sequences involving several muscles. Renal biopsy showed acute tubular injury. He was treated with steroids resulting in significant improvement. A repeat bone scan showed near complete resolution of the muscular uptake seen at presentation. This case nicely illustrates the role of bone scanning in the initial recognition and determination of the extent of polymyositis with identification of a suitable biopsy site as well as assessment of response to treatment.
https://aojnmb.mums.ac.ir/article_18855_8bd3b3c9b98153fbb51a670c4f169dde.pdf
2022-01-01
64
67
10.22038/aojnmb.2021.57818.1403
Polymyositis
Bone scan
MRI
Malik
Juweid
mjuweid@yahoo.com
1
Department of Radiology and Nuclear Medicine, School of Medicine, University of Jordan, Amman, Jordan
LEAD_AUTHOR
Noor
Mashhadani
noor89mail@gmail.com
2
Department of Radiology and Nuclear Medicine, School of Medicine, University of Jordan, Amman, Jordan
AUTHOR
Omar
Albtoush
o.albtoush@ju.edu.jo
3
Department of Radiology and Nuclear Medicine, School of Medicine, University of Jordan, Amman, Jordan
AUTHOR
Rahma
Doudeen
rahma_doudeen@yahoo.com
4
Department of Radiology and Nuclear Medicine, School of Medicine, University of Jordan, Amman, Jordan
AUTHOR
Ahmad
Al-Momani
ahmadmomani8797@gmail.com
5
School of Medicine, The University of Jordan, Amman, Jordan
AUTHOR
Mohammed
Aloqaily
maloqaily97@gmail.com
6
School of Medicine, The University of Jordan, Amman, Jordan
AUTHOR
Akram
Al-ibraheem
aibraheem@khcc.jo
7
Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan
AUTHOR
Jakubowski JK, Patel R, Buddharaju V. Polymyositis Presenting as Rhabdo-myolysis after the Initiation of Omeprazole. Cureus. 2020; 12(5):e8125.
1
Scott JA, Palmer EL, Fischman AJ. HIV-Associated Myositis Detected by Radio-nuclide Bone Scanning. J Nucl Med. 1989; 30(4):556-8.
2
Tomasová Studýnková J, Charvát F, Jarošová K, Vencovský J. The role of MRI in the assessment of polymyositis and dermato- Rheumatology. 2007; 46(7):1174-9.
3
Biyi A, Doudouh A. Muscular visualisation on a bone scan in paraneoplastic dermato-myositis associated with breast cancer Pan Afr Med J. 2016; 22:23:9.
4
An YS, Suh CH, Jung JY, Kim HA. Role of bone scan in the assessment of polymyositis/ dermatomyositis Clin Rheumatol. 2015; 34 (4):699-706.
5
Spies SM, Swift TR, Brown M. Increased 99mTc-polyphosphate muscle uptake in a patient with polymyositis: case report. J Nucl Med. 1975; 16(12):1125–7.
6
Steinfeld JR, Thorne NA, Kennedy TF. Positive 99mTc-pyrophosphate bone scan in polymyositis. Radiology. 1977; 122(1): 168.
7
Ramírez G, Asherson RA, Khamashta MA,Cervera R, D’Cruz D, Hughes GRV. Adult-onset polymyositis-dermatomyositis: Description of 25 patients with emphasis on treatment. Semin Arthritis Rheum. 1990; 20(2):114-20.
8
Strauss’ KW, Gonzalez-Buritica H, Khamashta MA, Hughes GR V. Polymyositis- dermato-myositis: a clinical Postgrad Med J. 1989; 65:437–43.
9
Lafforgue P, Siles S, Daumen-Legré V, Acquaviva PC. An unexpected, benign cause of increased muscular uptake at bone scintigraphy. Clin Exp Rheumatol. 1994; 12 (3):309–11.
10
Joshi D, Kumar N, Rai A. Dermatomyositis presenting with rhabdomyolysis and acute renal failure; an uncommon manifestation. Ann Indian Acad Neurol. 2009; 12(1):45–7.
11
ORIGINAL_ARTICLE
Knowledge and perception of nuclear medicine by radiologists in French-speaking sub-Saharan Africa
Objective(s): to assess the knowledge and perception of nuclear medicine by radiologists in French-speaking sub-Saharan Africa.
Methods: cross-sectional study conducted from April 8 to June 7 2020 including radiologists practicing in French-speaking sub-Saharan African countries. Data were collected electronically via a google form.
Results: Of the 142 radiologists surveyed, 45.8% had already completed an internship in Europe, 3.52% in a nuclear medicine department and 72.54% had a nuclear medicine department in their country of practice. Among these radiologists, 21.13% knew the three main techniques of nuclear medicine and only 9.15% knew that nuclear medicine allows functional, metabolic and molecular studies. On average, 56.8% were aware of clinical indications for the main fields of nuclear medicine. In 47.18% of cases, they thought that scintigraphic imaging was more irradiating than radiological imaging, 71.1% knew about hybrid imaging techniques, 43.66% had read a scientific article on nuclear medicine, 4.93% had attended a nuclear medicine conference and 28.9% had recommended a scintigraphic imaging examination in their report. Half of them would like to see nuclear medicine and radiology merged into a single specialty and 95.77% considered it essential to create a nuclear medicine department in their country.
Conclusion: The level of knowledge of radiologists in French-speaking sub-Saharan Africa about nuclear medicine was, on the whole, unsatisfactory with a generally encouraging perception.
https://aojnmb.mums.ac.ir/article_18864_fc905e8f4b1a83ccf23737f2743b23c8.pdf
2022-01-01
68
77
10.22038/aojnmb.2021.56679.1392
Nuclear Medicine
Medical Imaging
Scintigraphic Imaging Radiologists
French-speaking sub-Saharan Africa
Kokou
Adambounou
kadambounou@yahoo.fr
1
Biophysic and Medical Imaging departments, Campus Teaching Hospital, University of Lome, Togo
LEAD_AUTHOR
Koffi Assogba
Ahonhyi
ahonyiassogba@gmail.com
2
Radiology department, Campus Teaching Hospital, University of Lome, Togo
AUTHOR
Gilles David
Houndetoungan
fofodavid@yahoo.fr
3
Department of Biophysics and Nuclear Medicine, Faculty of Health Sciences of Cotonou, University of Abomey- Calavi, Benin
AUTHOR
Pakisba Ali
Ouedraogo
pakisbaali@gmail.com
4
Radiology department, Ouahigouya, University of Ouaga, Burkina Fasso
AUTHOR
Bidamin
Ntimon
ntimonbcamille@yahoo.fr
5
Radiology department, Campus Teaching Hospital, University of Lome, Togo
AUTHOR
Fabrice
Sodogas
fadogas11@gmail.com
6
Biophysic and Medical Imaging departments, Campus Teaching Hospital, University of Lome, Togo
AUTHOR
Lantam
Sonhaye
sonhayelantam@gmail.com
7
Radiology department, Campus Teaching Hospital, University of Lome, Togo
AUTHOR
Victor
Adjenou
kadjenou@yahoo.fr
8
Radiology department, Campus Teaching Hospital, University of Lome, Togo
AUTHOR
Arrivé L. Medical imaging for the clinician. Elsevier Masson, Paris 2012, 426 p.
1
French Society of Nuclear Medicine. White paper on nuclear medicine. Méd Nucl 2012; 36: 700-716.
2
Czernin J, Sonni I, Razmaria A, Calais J. The Future of Nuclear Medicine as an Independent Specialty. J Nucl Med 2019; 60:3S-12S.
3
Obioha FI. Nuclear medicine practice in Africa. West Afr JRadio 2008; 15: 22-27.
4
Amoussou-Guenou KM, Fachinan OH, Gbénou S, Komongui DG, Houndétoungan GD. Place of scintigraphy and radiotherapy in medical evacuations outside Benin from 2006 to 2010. Médecine Nucl. 2013; 37(10-11):507-10.
5
Adambounou K, Adjenou KV, Achy OB, Mossi KE, Gbande P, Adigo AMY. Knowledge and perception of nuclear medicine by Togolese physicians. Médecine Nucl. 2015; 39: e15-20.
6
Adigo YAM, Abdoulaye T, Djagnikpo O, Adambounou k, Konenin N, Agoda-koussema L. Frequency and sources of stress perceived by radiologists in French-speaking black Africa. African Journal of Medical Imaging. 2016:7.
7
Aurengo A, Petitclerc T, Kas A. Biophysics (4th Ed.). Lavoisier; Médecine science, 2013. 506 p.
8
Institute for Radiation protection and Nuclear Safety (IRSN). Analysis of data relating to the updating of diagnostic reference levels in radiology and nuclear medicine. Bilan 2007-2008. DRPH Report No. 2010-15.
9
Gervaise A, Esperabe-Vignau F, Pernin M, Portron Y, Naulet P, Lapierre- Combes M. Evaluation of CT prescribers' knowledge of patient radiation protection. J Radiol 2012; 92:681-7.
10
De Broucker T, Pontana F, Santangelo T,Faivre JB, Tacelli N, Delannoy-Deken V, et al. Single and dual-source chest CT protocols: levels of radiation dose in routine clinical practice. Diagn Interv Imaging 2012; 93: 852-8.
11
Lanza GM, Lamerichs R, Caruthers S, Wickline SA. Molecular Imaging in MR with targeted paramagnetic nanoparticles. Radiology and Nuclear medecine (S62). 2003. 34-7.
12
Heusch P, Nensa F, Schaarschmidt B, Sivanesapillai R, Beiderwellen K, Gomez B. Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology. Eur J Nucl Med Mol Imaging 2015; 42:42-48.
13
Netter F, Journo A, Mayer JC, Grandpierre S, Daragon N, Karcher G, Olivier P, S. Scigliano S. Contribution of SPECT-CT as a comple-ment to planar bone scintigraphy in the current practice of the nuclear medicine department of Nancy. Médecine Nucl 2008; 32:76-84.
14
Papathanassiou D, Bruna-Muraille C, Jouannaud C, Gagneux-Lemoussu L, Eschard JP, Liehn C. Single photon emission computed tomography and bone pathology. Revue du Rhumatisme 2009; 76: 843-850.
15
Caroli P, Nanni C, Rubello D, Alavi A, Fanti S. Non-FDG PET in the practice of oncology.Indian J Cancer 2010;47:120-125.
16
Doudouh A, Oueriagli SN, Biyi A. Value of FDG-PET in the early detection of bone metastases: a study of a series of 20 cases. Med Nucl 2013; 37:472-6.
17
PET imaging market summary report 2019. https://imvinfo.com/product/pet-imaging market-summary-report-2019. Accessed June 21, 2019.
18
Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, Bodei L, Buvat I, DiCarli M, Graham MM, Grimm J, Herrmann K, Kostakoglu L, Lewis JS, Mankoff DA, Peterson TE, Schelbert H, Schöder H, Siegel BA, Strauss HW. The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. J Nucl Med 2020; 6:263S-272S.
19
Lenzo NP, Meyrick D, Turner JH. Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer. Diagnostics (Basel) 2018; 8(1):16.
20
French Society of Radiology and French Society of Nuclear Medicine. Guide de bon usage des examens médicales. http://gbu. radiologie.fr/, accessed on 02 March 2021.
21
Bonnefoy PB, Prevot N, Bertoletti L, Sanchez A, Lima J, Font L. Use of ventilation/perfusion scintigraphy in patients diagnosed with pulmonary embolism-Data from the RIETE Registry. Medicine Nucl. 2019;43(2):174-5.
22
Adambounou K, Amoussou K, Bakai A. Perception of the place of scintigraphic imaging in the exploration of pulmonary embolism by cardiologists in French-speaking sub-Saharan Africa. Médecine Nucl. 2020; 44(2):128-9.
23
Halley A, Agostini D. Around synchronized myocardial tomoscintigraphy. Med Nucl 2007; 31:624-30.
24
Rouzet F, Guernou M, Chequer R, Lussato D, Hyafil F, Queneau M, et al. Dosimetric impact of new generation gamma cameras in nuclear cardiology. Med Nucl 2011; 35: 421-31.
25
Adambounou K, Mbodj M, Tapsoba TL,Gassama SS. Pediatric nuclear medicine examinations performed in Senegal from 2009 to 2017: general characteristics and diagnostic contribution. Médecine Nucl. 2018; 42(3):170.
26
Momin MA, Abdullah MN, Reza MS. Comparison of relative renal functions calculated with 99mTc-DTPA and 99mTc-DMSA for kidney patients of wide age ranges. Physica Medica 2018, 45: 99-105.
27
ORIGINAL_ARTICLE
Sectional Anatomy Quiz - VII
This series involves a quiz pertaining to the identification of key anatomical landmarks and normal structures present at a given level on the computed tomography (CT) image. The current quiz demonstrates examples of normal and abnormal axial CT images at the level of origin of the coeliac artery. The representative image is subsequently followed by further images demonstrating various commonly encountered pathologies found at this level in clinical practice. In each image, readers are expected to identify highlighted anatomical structures and appreciate how given pathologies can alter the appearance of normal structures. This series aims to advance understanding of sectional anatomy and aid nuclear physicians in the interpretation of the CT component of single photon emission computed tomography (SPECT) and positron emission tomography (PET) studies.
https://aojnmb.mums.ac.ir/article_18931_0cf1389a171a7a1c61ddbfae1daa31cc.pdf
2022-01-01
78
83
10.22038/aojnmb.2021.55113.1381
Computed Tomography
Sectional anatomy
abdomen
coeliac axis
coeliac artery
Nina
Li
ninajeanetteli@gmail.com
1
Rural Medical School, University of New South Wales (UNSW), Wagga Wagga, NSW, Australia
AUTHOR
Rashid
Hashmi
rashidhashmi@yahoo.com
2
Rural Medical School, University of New South Wales (UNSW), Wagga Wagga, NSW, Australia
LEAD_AUTHOR
No reference
1